Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6751)	1/20/1999 8:00:00 AM
From: Anthony Wong	Respond to of 9523

01/20 06:38 UCB's<UCBBt.BR>Zyrtec still has U.S. scope-report BRUSSELS, Jan 20 (Reuters) - Sales in the United States of the Zyrtec anti-allergy drug of Belgian drugs, fine chemicals and plastics films group UCB <UCBBt.BR> still have upside potential, BBL Vermeulen Raemdonck said on Wednesday. "We still believe in the important prospects of the drug in the U.S., the only Western market where it is not market leader," it said, adding fourth quarter sales had been slightly above expectations. Pfizer <PFE.N>, the U.S. co-marketer of Zyrtec, said on Tuesday fourth quarter sales of Zyrtec in the U.S. were $109 million, up 54 percent from the same 1997 quarter. Total 1998 sales were $416 million, up 57 percent. BBL Vermeulen Raemdonck said Zyrtec sales increased as a result of a successful direct-to-consumer advertising campaign and expanded field force support. On a firmer Brussels bourse, UCB shares were up 0.29 percent at 49.12 euros in volume of 110,584 at 1137 GMT. moneynet.com@NEWS-P1&Index=0&HeadlineURL=../News/NewsHeadlines.asp&DISABLE_FORM=&NAVSVC=News\Company